Skip to main content
Full access
REGULAR
Published Online: 1 October 2008

Predictors of Depression and Anxiety in Patients with Intracranial Neoplasms

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
D epression rates in patients with intracranial neoplasms have been reported to range from 19% to 93%, with most studies reporting prevalence rates between 10% and 30%. 14 Several studies have examined characteristics of depressed patients with brain tumors, 1, 35 but few have examined the presence and characteristics of anxiety in this population. 3, 6 The comorbidity of having a psychiatric illness with an intracranial tumor has been shown to result in multiple complications. 7, 8 Although there is an extensive literature examining the relationships between depression, anxiety, and cancer, few systematic studies have addressed their occurrence specifically in association with brain tumors.
METHOD
A consecutive series of deceased patients with diagnoses of primary or metastatic brain cancer who were admitted to the Johns Hopkins Hospital between September 1995 and January 2007 was obtained using billing codes. Fifty-six cases were excluded due to inadequate records or because the patient was under 5 years of age. Medical records were examined for demographic data, tumor type, location, size, treatment modalities, survival time, and premorbid psychiatric diagnoses. Treating physicians’ diagnoses of depression and anxiety or data in the chart that were suggestive of either disorder according to DSM-IV criteria, were noted. Diagnostic or severity scales were not utilized in the assessment of affective disorders. The use of antidepressants and concurrent treatment by a psychiatrist were also recorded. Data were analyzed using chi-square and ANOVA analyses using SPSS 15.0 software (Chicago, Ill.). This study was approved by the Johns Hopkins Hospital Institutional Review Board.

RESULTS

Table 1 summarizes characteristics of the study population (N=301). There was an even cerebral distribution of single site tumors. Ninety-four (31%) individuals had bilateral tumors. Depression was the most common premorbid psychiatric disorder (n=18, 6%) followed by substance abuse (n=17, 6%) and anxiety disorders (n=16, 5%). Comorbid depression was diagnosed in 45 individuals (15%), 35 individuals had anxiety disorders (12%), and 13 patients had both disorders following the diagnosis of a brain tumor (4%). Thirty-four depressed patients (75%) were prescribed antidepressants, and 12 were seen by a psychiatrist at some point during their illness (27%). Depression was reported as frequently in males (n=21, 47%) as in females (n=24, 53%), but diagnoses of anxiety were more prevalent in females (n=26, 74%, p=0.01). Race, marital status, tumor type, location, and size were not found to be predictive of either disorder. Premorbid depression (n=18, 40%, p<0.001) and anxiety (n=16, 46%, p<0.001) were found to be highly predictive of future psychiatric illness in the setting of brain tumors using bivariate analyses. Survival times varied for patients with depression (11 months), anxiety (7 months), both disorders (3.5 months), and neither disorder (9 months), but were not statistically significant (p=0.69). Thirty patients with depression (67%, p=0.067) were given whole brain radiation treatments while 22 individuals with anxiety (63%) received radiation therapy (p=0.058). Eight patients with both disorders (62%) underwent whole brain radiation treatment.
TABLE 1. Demographic Data of Study Population (N=301)

DISCUSSION

Depression and anxiety rates, as detected by internists and oncologists in this study, were similar to the 12-month prevalence rate in the general population. 9 The rate of comorbid anxiety and depression (4%) was less than expected. However, many studies have found underestimation of depression and anxiety in the medically ill. 10 This and the lack of a formal concurrent psychiatric assessment suggest that the prevalence rates for these disorders may not be accurately reported. Interestingly, reported depression rates were relatively equivalent in both genders, a finding that is contradictory to the 2:1 ratio of female to male depression rates noted in both general and stroke population studies. 9, 11 This could be attributed to the erroneous notion that the equal prevalence rates of brain tumors across gender relate to equal prevalence rates of depressive episodes in both males and females. In the general population, the female to male ratio for anxiety disorders is also approximately 2:1 9 ; however, the ratio neared 3:1 in this study. This suggests that females with brain tumors may be particularly susceptible to anxiety disorders, though this may also be attributable to gender bias. 12
In this study, the most common correlate of reported depression and anxiety in brain tumor patients was a premorbid diagnosis of either disorder. Sixty-one percent of patients with a premorbid diagnosis of depression were deemed depressed after being diagnosed with an intracranial neoplasm while 63% of premorbidly anxious patients had a recurrence of symptoms, both of which were statistically significant findings. Because the current study examined physician-reported rates of psychiatric illness, it is possible that clinicians were more apt to diagnose patients who had previously been diagnosed with a psychiatric illness. Nonetheless, we recommend that a past psychiatric history be obtained when evaluating patients with brain tumors and that those patients with a history of depression or anxiety be monitored closely. Further studies should address whether prophylactic antidepressant therapy is warranted as this has been shown to significantly reduce depression rates in patients following stroke. 13 Although the results did not reach statistical significance in this study, data suggest that survival time may be shortened by depression and anxiety as previously reported. 2, 7
There are several limitations to this study. First, data were derived from records that may not have accurately portrayed patient symptoms, as standardized psychiatric assessments were not performed. This may have resulted in erroneous documentation of comorbid and premorbid psychiatric diagnoses. Because the study was conducted at a tertiary care hospital, this may also have biased tumor type and illness severity.
In summary, psychiatric illnesses in brain cancer patients may be underdiagnosed and undertreated for a variety of reasons, 14, 15 possibly resulting in decreased survival times in patients with anxiety and in those with both depression and anxiety. Routine use of screening tools for depression and anxiety may improve the detection rate of these two illnesses within the neurooncological setting. Premorbid depression and anxiety are the strongest predictors of subsequent psychiatric illness and females may be especially susceptible to anxiety symptoms. Patients exposed to whole brain radiation treatment may also be at increased risk of developing a psychiatric illness, as has been previously suggested. 16

Footnote

Received September 11, 2007; revised October 17, 2007; accepted October 25, 2007. Dr. Brian Appleby and Dr. Rabins are affiliated with the Division of Geriatric Psychiatry and Neuropsychiatry at Johns Hopkins University School of Medicine in Baltimore, M.D.; Dr. Kristin Appleby is affiliated with the Department of Neurology at Georgetown University Hospital in Washington, D.C.; Address correspondence to Brian S. Appleby, M.D., Meyer 279, The Johns Hopkins Hospital, 600 North Wolfe St., Baltimore, MD 21287; [email protected] (e-mail).
Copyright © 2008 American Psychiatric Publishing, Inc.

References

1.
Pringle AM, Taylor R, Whittle IR: Anxiety and depression in patients with an intracranial neoplasm before and after tumor surgery. Br J Neurosurg 1999; 13:46–51
2.
Litofsky NS, Farace E, Anderson F, et al: Depression in patients with high-grade glioma: results of the glioma outcomes project. Neurosurgery 2004; 54:358–367
3.
Aass N, Fosså SD, Dahl AA, et al: Prevalence of anxiety and depression in cancer patients seen at Norwegian radium hospital. Eur J Cancer 1997; 33:1597–1604
4.
Wellisch DK, Kaleita TA, Freeman D, et al: Predicting major depression in brain tumor patients. Psychooncology 2002; 11:230–238
5.
Brown PD, Maurer MJ, Rummans TA, et al: A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005; 57:495–504
6.
Kilbride L, Smith G, Grant R: The frequency and cause of anxiety and depression amongst patients with malignant brain tumors between surgery and radiotherapy. J Neurooncol 2007; 84:297–304
7.
Mainio A, Hakko H, Timonen M, et al: Depression in relation to survival among neurosurgical patients with a primary brain tumor: a 5-year follow-up study. Neurosurgery 2005; 56:1234–1242
8.
Mainio A, Hakko H, Niemelä A, et al: Gender difference in relation to depression and quality of life among patients with a primary brain tumor. Eur Psychiatry 2006; 21:194–199
9.
Kessler RC, McGonagle KA, Zhao S, et al: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994; 51:8–19
10.
Coyne JC, Schwenk TL, Fechner-Bates S: Nondetection of depression by primary care physicians reconsidered. Gen Hosp Psychiatry 1995; 17:3–12
11.
Paradiso S, Robinson RG: Gender differences in poststroke depression. J Neuropsychiatry Clin Neurosci 1998; 10:41–47
12.
Lewis R, Lamdan RM, Wald D, et al: Gender bias in the diagnosis of a geriatric standardized patient: a potential confounding variable. Acad Psychiatry 2006; 30:392–396
13.
Chen Y, Patel NC, Guo JJ, et al: Antidepressant prophylaxis for poststroke depression: a meta-analysis. Int Clin Psychopharmacol 2007; 22:159–166
14.
Greenberg DB: Barriers to the treatment of depression in cancer patients. J Natl Cancer Inst Monogr 2004; 32:127–135
15.
Raison CL, Miller AH: Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry 2003; 54:283–294
16.
Chow E, Davis L, Holden L, et al: Prospective assessment of patient-rated symptoms following whole brain radiotherapy for brain metastases. J Pain Symptom Manage 2005; 30:18–23

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: 447 - 449
PubMed: 19196929

History

Published online: 1 October 2008
Published in print: Fall, 2008

Authors

Details

Brian S. Appleby, M.D.
Kristin K. Appleby, M.D.
Peter V. Rabins, M.D., M.P.H.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share